CEPHACARE FLAVOUR 250 MG TABLETS FOR DOGS

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

CEFALEXIN (AS CEFALEXIN MONOHYDRATE) PH. EUR

Available from:

Animalcare Limited

ATC code:

QJ01DB01

INN (International Name):

CEFALEXIN (AS CEFALEXIN MONOHYDRATE) PH. EUR

Dosage:

250 mg/tablet

Pharmaceutical form:

Tablets

Prescription type:

POM

Therapeutic group:

Canine

Therapeutic area:

Cefalexin

Therapeutic indications:

Antibacterial

Authorization status:

Authorised

Authorization date:

2008-12-19

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Cephacare flavour 250 mg tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
250 mg cefalexin as cefalexin monohydrate.
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablets
Beige, flat tablets with a break mark on one side.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of infections of the respiratory tract, gastro-intestinal tract, urogenital tract, the skin and localised infections
in soft tissue caused by bacteria sensitive to cefalexin.
4.3 CONTRAINDICATIONS
Do not use in cases of known hypersensitivity to the active substance, to other cephalosporins, to other substances of
the -lactam group or to any of the excipients.
Do not use in rabbits, gerbils, guinea pigs and hamsters.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 05/06/2014_
_CRN 7016540_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use of the product should be based on susceptibility testing and take into account official and local antimicrobial
policies.
Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to
cefalexin and may decrease the effectiveness of treatment with penicillins, due to the potential for cross resistance.
In the case of an allergic reaction, treatment should be withdrawn.
As with other antibiotics which are excreted mainly by the kidneys, unnecessary accumulation may occur in the body
when renal function is impaired. In cases�